{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:01:31Z","timestamp":1760385691616,"version":"3.40.5"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/j.idcr.2019.e00493","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T06:33:40Z","timestamp":1548570820000},"page":"e00493","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Chronic prostatitis caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli managed using oral fosfomycin\u2014A case report"],"prefix":"10.1016","volume":"15","author":[{"given":"Francisco","family":"Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Santos Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2077-3356","authenticated-orcid":false,"given":"Andr\u00e9","family":"Silva Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f3nio","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2009","series-title":"ECDC\/EMEA joint technical report. The bacterial challenge: time to react. A call to narrow the gap between multidrugresistant bacteria in the EU and the development of new antibacterial agents","author":"ECDC\/EMEA","key":"10.1016\/j.idcr.2019.e00493_bib0005"},{"key":"10.1016\/j.idcr.2019.e00493_bib0010","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idcr.2019.e00493_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idcr.2019.e00493_bib0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","article-title":"Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection","volume":"22","author":"Senol","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.idcr.2019.e00493_bib0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.idcr.2019.e00493_bib0030","first-page":"57","article-title":"Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-\u03b2-lactamase-producing Escherichia coli in a foreign-body infection model","author":"Corvec","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idcr.2019.e00493_bib0035","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1086\/652861","article-title":"Treatment of bacterial prostatitis","volume":"50","author":"Lipsky","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2019.e00493_bib0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/cid\/cit704","article-title":"Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?","volume":"58","author":"Gardiner","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2019.e00493_bib0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2014.12.019","article-title":"Persistent extended-spectrum Beta-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline","volume":"45","author":"Cunha","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idcr.2019.e00493_bib0050","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/AAC.02611-15","article-title":"Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis","volume":"60","author":"Los-Arcos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idcr.2019.e00493_bib0055","article-title":"Oral fosfomycin for the treatment of chronic prostatitis","author":"Karaiskos","year":"2015","journal-title":"Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2015)"},{"key":"10.1016\/j.idcr.2019.e00493_bib0060","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/cid\/civ436","article-title":"Fosfomycin for treatment of prostatitis: new tricks for old dogs","volume":"61","author":"Grayson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2019.e00493_bib0065","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijantimicag.2016.02.009","article-title":"Raoultella planticola chronic bacterial prostatitis with prostatic calcifications: successful treatment with prolonged fosfomycin therapy","volume":"47","author":"Gian","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idcr.2019.e00493_bib0070","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1525-1497.2001.01223.x","article-title":"Quality of life is impaired in men with chronic prostatitis: the chronic prostatitis collaborative research network","volume":"16","author":"McNaughton Collins","year":"2001","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.idcr.2019.e00493_bib0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QCO.0000000000000222","article-title":"Bacterial prostatitis","volume":"29","author":"Gill","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.idcr.2019.e00493_bib0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1574-695X.2010.00659.x","article-title":"Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications","author":"Mazzoli","year":"2010","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.idcr.2019.e00493_bib0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.juro.2006.08.081","article-title":"Biofilm formation in uropathogenic Escherichia coli strains: relationship with prostatitis, urovirulence factors and antimicrobial resistance","volume":"177","author":"Soto","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.idcr.2019.e00493_bib0090","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00345-013-1145-9","article-title":"The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study","volume":"32","author":"Bartoletti","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.idcr.2019.e00493_bib0095","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","article-title":"Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idcr.2019.e00493_bib0100","first-page":"3","article-title":"FOREST Study Group. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial","volume":"31","author":"Rosso-Fern\u00e1ndez","year":"2015","journal-title":"BMJ Open"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250918301938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250918301938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T12:23:46Z","timestamp":1558441426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250918301938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":20,"alternative-id":["S2214250918301938"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2019.e00493","relation":{},"ISSN":["2214-2509"],"issn-type":[{"type":"print","value":"2214-2509"}],"subject":[],"published":{"date-parts":[[2019]]},"article-number":"e00493"}}